new to Hou

Exclusive: Canadian energy software company plans to grow local team and open Houston office

A Canadian software company is expanding its presence in Houston to meet the needs of its clients. Photo via Getty Images

One of the biggest obstacles heavy industry tech startups face — especially in oil and gas — is getting that first big customer, says Vicki Knott, co-founder and CEO of Crux OCM.

"Our biggest challenge is nobody wants to be first in energy," she tells InnovationMap.

But Crux OCM, based in Calgary, overcame that challenge and currently counts Houston-based Phillips 66 among its clients. The two companies announced a pilot program for Crux OCM's pipeBOT technology earlier this year.

Crux OCM's technology focuses on automating the control room operations — something that, like most automation software, increases revenue and reduces errors. The company, which was founded in 2017, also allows its clients consistency and reliability with its software.

"Even though the pumps and the equipment are automated, control room operators are still executing procedures, checklist, and rules of thumb on their own via screens," Knott says. "If you think of pilots and planes have autopilot software, why don't our control room operators? That's really the problem we set out to tackle."

Vicki Knott is co-founder and CEO of Crux OCM. Photo courtesy

Automation is certainly a growing opportunity for energy companies — especially in light of the pandemic that forced remote work and less on-site personnel across industries. Knott says just over a year ago, Crux OCM saw increased interest.

"We had a couple customers who had their capital budget cut when the pandemic hit and when oil went negative, and we had a couple customers who said they were doubling down on software like this," Knott explains.

The company has raised $3 million in venture funding, backed by Root Ventures, Angular Ventures, and Golden Ventures. Knott says another funding round is on the horizon as is growth for its Houston presence.

Crux OCM currently has three full-time Houston employees and is looking to grow that team in the next six months. Specifically, the local team will focus on sales, as well as product development, as the company's head of sales and senior product manager are both based here. As the local clientbase grows, Knott says they will also need to hire deployment engineers as well.

A new office to support this growing team is also in the works. Knott says she's looking for space in North Houston, and, depending on how comfortable people are returning to offices and meetings, it could open as early as later this year.

Calgary and Houston have a lot in common, Knott says, and she sees a very natural connection to the two regions. Knott plans to work six months of the year in Houston with the local office.

"A lot of the companies that head offices in Houston, they have head offices in Calgary," she says. "If a startup in Houston is getting traction, I think there's a natural movement to start in the Calgary market and vice versa."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted